H
Hua Zhang
Researcher at National Institutes of Health
Publications - 27
Citations - 7424
Hua Zhang is an academic researcher from National Institutes of Health. The author has contributed to research in topics: T cell & CD8. The author has an hindex of 19, co-authored 26 publications receiving 6555 citations.
Papers
More filters
Journal ArticleDOI
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
TL;DR: CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Journal ArticleDOI
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
TL;DR: Evidence is presented that the LAK system is a phenomenon distinct from either NK or CTL systems that probably accounts for a large number of reported nonclassical cytotoxicities and may be functional in immune surveillance against human solid tumors.
Journal ArticleDOI
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy
Steven L. Highfill,Yongzhi Cui,Amber J. Giles,Jillian P. Smith,Hua Zhang,Elizabeth Morse,Rosandra N. Kaplan,Crystal L. Mackall +7 more
TL;DR: CXCR2+CD11b+Ly6Ghi MDSCs mediate local immunosuppression, which limits the efficacy of checkpoint blockade in murine RMS, and is identified as a novel target for modulating tumor immune escape.
Journal ArticleDOI
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets
Claude Sportes,Frances T. Hakim,Sarfraz Memon,Hua Zhang,Kevin S. Chua,Margaret R. Brown,Thomas A. Fleisher,Michael Krumlauf,Rebecca Babb,Catherine Chow,Terry J. Fry,Julie Engels,Renaud Buffet,Michel Morre,Robert J. Amato,David Venzon,Robert Korngold,Andrew L. Pecora,Ronald E. Gress,Crystal L. Mackall +19 more
TL;DR: It is suggested that rhIL-7 therapy could enhance and broaden immune responses, particularly in individuals with limited naive T cells and diminished TCR repertoire diversity, as occurs after physiological (age), pathological (human immunodeficiency virus), or iatrogenic (chemotherapy) lymphocyte depletion.
Journal ArticleDOI
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells
Hua Zhang,Kevin S. Chua,Martin Guimond,Veena Kapoor,Margaret V. Brown,Thomas A. Fleisher,Lauren M. Long,Donna Bernstein,Brenna J. Hill,Daniel C. Douek,Jay A. Berzofsky,Charles S. Carter,Elizabeth J. Read,Lee J. Helman,Crystal L. Mackall +14 more
TL;DR: It is suggested that IL-2 and lymphopenia are primary modulators of CD4+CD25+ Treg cell homeostasis, and Treg cells generated byIL-2 therapy expressed similar levels of FOXP3 and had similar potency for suppression compared to T Reg cells present in normal hosts.